Abstracts tagged "juvenile idiopathic arthritis (JIA) and quality of life"

Abstract Number: 1467 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Reduced in Pediatric Patients with Juvenile Idiopathic Arthritis and Juvenile-Onset Fibromyalgia
Michal Feldon¹, Catherine Donnelly², Hermine I. Brunner³, Anne Louis Johnson¹, Lukasz Itert⁴, Lisa G Rider⁵ and Edward H. Giannini³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Internal Medicine, University of Cincinnati, Cincinnati, OH, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD
Background/Purpose : A number of validated measures are now available for the evaluation of health related quality of life (HRQOL) in children with rheumatic diseases,…
Abstract Number: 2022 • 2012 ACR/ARHP Annual Meeting
Individual Disease Burden in Children and Adolescents with Chronic Musculoskeletal Pain – Multilevel-Analysis of a Nationwide Prospective Longitudinal Observation Study
Kerstin Gerhold¹, Rebecca Muckelbauer², Jacqueline Müller-Nordhorn², Angelika Thon³, Thomas Müller⁴, Gerd Ganser⁵, Martina Niewerth⁶ and Kirsten Minden⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Berlin School of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, ⁴Universitätsklinikum Halle (Saale), Halle (Saale), Germany, ⁵Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁶Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ⁷Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany
Background/Purpose: Chronic musculoskeletal pain was described to be a frequent complaint in children and adolescents with assumed relevant impairment of health-related quality of life (HRQoL)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].